Stratagene is free to continue selling its competent-cell products until a district court addresses a patent suit between the firm and Invitrogen again, according to an Invitrogen official.

Invitrogen said that a US appeals court ruled in its favor in a four-year-old patent-infringement suit against Stratagene. The appeal overturned a 2002 decision by a federal district court in Texas and ruled that Stratagene infringes a patent involving a process for developing competent cell products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.